MedTrace Logo

PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients

NCT01020604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1376

Last updated 2013-04-30

No results posted yet for this study

Summary

The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure after radical prostatectomy. Other prospective studies have shown no adverse effect of obesity on long-term outcomes after prostatectomy. Limited reports are available on the impact of obesity on prostate cancer progression after radiotherapy. Primary: to assess percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Secondary: to determine the Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire

Conditions

Sponsors & Collaborators

Principal Investigators

  • Istvan Buzogany · Budapest City's Local Government "Péterfy Sándor" Hospital and Ambulatory Clinic

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020604 on ClinicalTrials.gov